Although this drug shows a very high clinical efficiency in metastatic melanoma patients harboring the BRAF V600E mutation, a wide type of BRAF melanoma tumors do not respond to PLX4032 or, in some cases, important clinical side effects limit the use of this drug, such as skin lesions and even cutaneous squamous cell carcinoma. This evidence concerns the gene BRAF and melanoma.